Conditions: HIV Coinfection
Keywords: HIV coinfection maraviroc CCR5 blocker entry inhibitor liver disease viral hepatitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 138
Healthy volunteers: no

Brief summary:
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Maraviroc intervention 2: Placebo
Intervention descriptions: intervention 1: 150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy intervention 2: 150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy

Protocol document: